Trial Profile
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs MB 107 (Primary) ; Busulfan
- Indications Immunodeficiency disorders; X-linked genetic disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LVXSCID-ND
- 14 Apr 2023 Status changed from recruiting to suspended.
- 19 May 2022 According to a Mustang Bio media release, UCSF Benioff Children's Hospital in San Francisco is one of the clinical site of the study.
- 19 May 2022 According to a Mustang Bio media release, interim data from this trial were presented at the 25th American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.